石药集团(01093.HK)SYH2059片获准在中国开展临床试验

阿斯达克财经
07 Jan

石药集团(01093.HK) 公布,集团开发的SYH2059片已获中国国家药品监督管理局批准,可以在中国开展临床试验。
该产品由集团小分子药物创新设计平台研发,是一款全新的、具有完全自主知识产权的高活性与高选择性的环核苷酸磷酸二酯酶4B(PDE4B)抑制剂。是次获批的临床适应症为间质性肺疾病,包括但不限于特发性肺纤维化、进展性肺纤维化。
集团指,目前市场上治疗间质性肺疾病的药物为数不多,且患者治疗获益有限,该产品有望成为该疾病的有效治疗药物,具有较大临床开发价值。(sl/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-07 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10